A Canada-based firm, Sernova Corp. has completed the initial closing of 2,333,500 dollars of its private placement without a contract. The clinical program of Sernova will be funded by the net proceeds from the increased portion of the private placement inclusive of its Phase I/II regenerative medicine clinical trial has been approved by US Food and drug administration and for the advancement of academic/corporate collaborations using the firm’s platform technology for the treatment of hemophilia, diabetes, and other serious disease conditions, as well as, for strengthening relations with investor and common corporate purposes.
Phase I or II non-randomized will be inclusive of diabetic subjects with the enrollment of hypoglycemia unawareness into the study. There will be implantation of Cell Pouches into participants. Succeeding the process of developing vascularized tissue chambers within the Cell Pouch, then there is stabilization of subjects on immunosuppression, and under strict release criteria, a dose of purified islets is then transplanted into the Cell Pouch.
It has been claimed by the researchers there is a greater need for more psychological support and longer follow-up for the children who are affected, as well as, their parents. It has been already found that adults with IBD are at a greater risk of psychiatric disorders. Now it has been revealed by the latest study that children with IBD also are at increased risk of mental health problems, the researchers told. Over 6,400 children affected with IBD, were included in the study who were born between 1973 and 2013. Nearly 17 percent of the children with IBD were given a psychiatric diagnosis comparatively to just under 12 percent of the healthy children and about 10 percent of the siblings during an average follow-up period of 9 years. This meant that there was a 1.6 times greater risk of psychiatric disorders in children with IBD when compared with Swedish children from the general population.